The battle to be the best-selling SGLT2 inhibitor continues to heat up after AstraZeneca PLC revealed data demonstrating that Farxiga, like Boehringer Ingelheim GmbH/Eli Lilly and Company's rival therapy Jardiance, is an effective treatment for heart failure regardless of ejection fraction.
The UK major has presented topline results from the DELIVER Phase III trial which showed that Farxiga/Forxiga (dapagliflozin) reduced the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
